科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002422 科伦药业

已收盘 04-30 15:00:00

{"stockData":{"symbol":"002422","market":"SZ","secType":"STK","nameCN":"科伦药业","latestPrice":33.95,"timestamp":1714460619000,"preClose":32.83,"halted":0,"volume":23105049,"delay":0,"floatShares":1307000000,"shares":1602000000,"eps":1.6684,"marketStatus":"已收盘","marketStatusCode":5,"change":1.12,"latestTime":"04-30 15:00:00","open":32.75,"high":34.64,"low":32.58,"amount":785000000,"amplitude":0.0627,"askPrice":33.95,"askSize":75,"bidPrice":33.93,"bidSize":5,"shortable":0,"etf":0,"ttmEps":1.6684,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":32.83,"symbolType":"stock","openAndCloseTimeList":[[1714440600000,1714447800000],[1714453200000,1714460400000]],"highLimit":36.11,"lowLimit":29.55,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1601592173,"pbRate":2.36,"roa":"--","roe":"4.9%","epsLYR":1.69,"committee":-0.634146,"marketValue":54374000000,"floatMarketCap":44371000000,"peRate":20.348837,"changeRate":0.0341,"turnoverRate":0.0177,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-05-06。"},"requestUrl":"/m/hq/s/002422/wiki","defaultTab":"wiki","newsList":[{"id":"2432558894","title":"科伦药业获得发明专利授权：“一种灭菌器升温控制方法、系统及存储介质”","url":"https://stock-news.laohu8.com/highlight/detail?id=2432558894","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2432558894?lang=zh_cn&edition=full","pubTime":"2024-05-01 02:45","pubTimestamp":1714502727,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示科伦药业新获得一项发明专利授权，专利名为“一种灭菌器升温控制方法、系统及存储介质”，专利申请号为CN202210174860.1，授权日为2024年4月30日。今年以来科伦药业新获得专利授权15个，较去年同期增加了25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050100003963.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431621380","title":"交银国际证券：给予科伦药业买入评级，目标价位40.0元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431621380","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431621380?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:17","pubTimestamp":1714447066,"startTime":"0","endTime":"0","summary":"交银国际证券有限公司李柳晓,丁政宁近期对科伦药业进行研究并发布了研究报告《2023/1Q24业绩强劲增长，重点关注原料药和创新业务，上调目标价》，本报告对科伦药业给出买入评级，认为其目标价位为40.00元，当前股价为34.12元，预期上涨幅度为17.23%。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级6家，增持评级2家；过去90天内机构目标均价为45.48。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000024310.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431380754","title":"东海证券：给予科伦药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431380754","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431380754?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:38","pubTimestamp":1714441125,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏,伍可心近期对科伦药业进行研究并发布了研究报告《公司简评报告：大输液原料药快速增长，创新药持续兑现》，本报告对科伦药业给出买入评级，当前股价为33.14元。非输液药品销售收入39.55亿元，同比下降6.93%，受集采等因素影响，部分产品销售下滑。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级6家，增持评级2家；过去90天内机构目标均价为45.48。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000019217.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431185741","title":"华安证券：给予科伦药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431185741","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431185741?lang=zh_cn&edition=full","pubTime":"2024-04-29 20:55","pubTimestamp":1714395344,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超近期对科伦药业进行研究并发布了研究报告《23FY三发驱动创新增长，结构优化降本增效》，本报告对科伦药业给出买入评级，当前股价为32.83元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级6家，增持评级2家；过去90天内机构目标均价为45.48。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900030710.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431583099","title":"西南证券：给予科伦药业买入评级，目标价位39.38元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431583099","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431583099?lang=zh_cn&edition=full","pubTime":"2024-04-29 19:22","pubTimestamp":1714389741,"startTime":"0","endTime":"0","summary":"西南证券股份有限公司杜向阳近期对科伦药业进行研究并发布了研究报告《输液业务表现亮眼，创新转型加速兑现》，本报告对科伦药业给出买入评级，认为其目标价位为39.38元，当前股价为32.83元，预期上涨幅度为19.95%。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级6家，增持评级2家；过去90天内机构目标均价为45.48。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900026078.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430794295","title":"科伦药业：东海证券、摩根士丹利等多家机构于4月25日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2430794295","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430794295?lang=zh_cn&edition=full","pubTime":"2024-04-26 09:56","pubTimestamp":1714096611,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年4月26日科伦药业发布公告称东海证券、摩根士丹利、瑞银证券、太平洋证券、西南证券、信达证券、兴业证券、银河证券、浙商证券、中金医药、中泰证券、广发证券、中信建投证券、中信证券、中邮证券、投资者、国海证券、国盛证券、国信证券、海通证券、华创证券、华泰证券、开源证券于2024年4月25日调研我司。科伦博泰 3 月底公布年度业绩，2023年实现 15.4亿收入，大部分来自海外合作伙伴。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600022310.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430260822","title":"科伦药业（002422）4月25日主力资金净买入3414.12万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430260822","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430260822?lang=zh_cn&edition=full","pubTime":"2024-04-26 09:13","pubTimestamp":1714094033,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月25日收盘，科伦药业报收于31.3元，上涨4.13%，换手率2.22%，成交量28.97万手，成交额9.01亿元。近5日资金流向一览见下表：科伦药业融资融券信息显示，融资方面，当日融资买入7179.34万元，融资偿还5579.16万元，融资净买入1600.18万元，连续3日净买入累计3475.54万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600020393.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430409180","title":"中国银河：给予科伦药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430409180","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430409180?lang=zh_cn&edition=full","pubTime":"2024-04-25 19:35","pubTimestamp":1714044922,"startTime":"0","endTime":"0","summary":"中国银河证券股份有限公司程培,孙怡近期对科伦药业进行研究并发布了研究报告《输液龙头业绩亮眼，需求旺盛可持续性较高》，本报告对科伦药业给出买入评级，当前股价为31.3元。2023年公司抗生素中间体及原料药实现收入48.43亿元，同比增长23.78%。　　科伦博泰里程碑收入持续兑现，SKB264上市在即备战商业化。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级1家，增持评级2家；过去90天内机构目标均价为40.0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500041046.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430610214","title":"图解科伦药业一季报：第一季度单季净利润同比增26.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430610214","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430610214?lang=zh_cn&edition=full","pubTime":"2024-04-25 01:49","pubTimestamp":1713980955,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业2024年一季报显示，公司主营收入62.19亿元，同比上升10.32%；归母净利润10.26亿元，同比上升26.0%；扣非净利润9.92亿元，同比上升25.67%；负债率31.33%，投资收益1.12亿元，财务费用1683.13万元，毛利率55.84%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500002505.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429457355","title":"科伦药业(002422.SZ)发布一季度业绩，净利润10.26亿元，增长26.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429457355","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429457355?lang=zh_cn&edition=full","pubTime":"2024-04-24 22:42","pubTimestamp":1713969735,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)发布2024年一季度报告，报告期内实现营业收入62.19亿元，同比增长10.32%。归属于上市公司股东的净利润10.26亿元，同比增长26.00%。归属于上市公司股东的扣除非经常性损益的净利润9.92亿元，同比增长25.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109394.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429452182","title":"科伦药业(002422.SZ)发布2023年度业绩，净利润24.56亿元，增长44.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429452182","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429452182?lang=zh_cn&edition=full","pubTime":"2024-04-24 22:39","pubTimestamp":1713969599,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)发布2023年年度报告，报告期内，公司实现营业收入214.54亿元，同比增长12.69%。实现归属于上市公司股东的净利润24.56亿元，同比增长44.03%。实现归属于上市公司股东的扣除非经常性损益的净利润23.66亿元，同比增长43.77%。基本每股收益为1.69元。拟向全体股东每10股派发现金红利8元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109387.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429454225","title":"科伦药业最新公告：2023年净利润同比增长44.03% 拟10派8元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429454225","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429454225?lang=zh_cn&edition=full","pubTime":"2024-04-24 22:19","pubTimestamp":1713968376,"startTime":"0","endTime":"0","summary":"科伦药业披露一季报，2024年第一季度实现营业收入62.19亿元，同比增长10.32%；净利润10.26亿元，同比增长26%。科伦药业同时披露年报，2023年实现营业收入214.54亿元，同比增长12.69%；净利润24.56亿元，同比增长44.03%；基本每股收益1.69元。公司拟每10股派发红利8元（含税）。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400046752.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429405962","title":"脑机接口又传重磅利好！全球最大神经拟态系统诞生，比人脑快200倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2429405962","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2429405962?lang=zh_cn&edition=full","pubTime":"2024-04-22 10:24","pubTimestamp":1713752640,"startTime":"0","endTime":"0","summary":"英特尔打开AGI时代的一把“钥匙”？","market":"hk","thumbnail":"https://img3.gelonghui.com/9112e-0d1877a9-cc43-44da-abd0-0da5aff2eb86.png?guru_height=291&guru_width=480","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9112e-0d1877a9-cc43-44da-abd0-0da5aff2eb86.png?guru_height=291&guru_width=480"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/722215","is_publish_highlight":false,"gpt_icon":0},{"id":"2426462039","title":"科伦药业(002422.SZ)发预增，预计第一季度净利润9.5亿元–11亿元，同比增长16.64%-35.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426462039","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2426462039?lang=zh_cn&edition=full","pubTime":"2024-04-10 19:22","pubTimestamp":1712748120,"startTime":"0","endTime":"0","summary":"科伦药业发布2024年第一季度业绩预告，公司预计第一季度归属于上市公司股东的净利润9.5亿元–11亿元，同比增长16.64%-35.06%;扣除非经常性损益后的净利润9亿元–10.4亿元，同比增长13.41%-31.05%。股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-10/doc-inarizht0024666.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-10/doc-inarizht0024666.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419547623","title":"科伦药业(002422.SZ)：科伦博泰核心产品SKB264(MK-2870)获突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2419547623","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2419547623?lang=zh_cn&edition=full","pubTime":"2024-03-13 11:53","pubTimestamp":1710301980,"startTime":"0","endTime":"0","summary":"科伦药业发布公告，公司控股子公司四川科伦博泰生物医药股份有限公司核心产品SKB264于近日就一线治疗不可手术切除的局部晚期、复发或转移性PD-L1阴性三阴性乳腺癌获国家药品监督管理局药品审评中心突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-13/doc-inanczhq9626027.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-13/doc-inanczhq9626027.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2418335135","title":"科伦药业(002422.SZ)子公司主要产品A400(EP0031)获FDA授予快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2418335135","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2418335135?lang=zh_cn&edition=full","pubTime":"2024-03-11 17:21","pubTimestamp":1710148860,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)公告，公司于近日获悉，公司控股子公司四川科伦博泰生物医药股份有限公司(简称：“科伦博泰”)主要产品A400(在转染过程中重排(RET)小分子激酶抑制剂项目，亦称为KL590586或EP0031)获得了美国食品药品监督管理局(FDA)授予的快速通道资格认定，用于治疗RET融合阳性非小细胞肺癌(NSCLC)。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-11/doc-inamxxsp1532553.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-11/doc-inamxxsp1532553.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2404606523","title":"科伦药业(002422.SZ)子公司奥拉帕利片获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2404606523","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2404606523?lang=zh_cn&edition=full","pubTime":"2024-01-19 16:00","pubTimestamp":1705651200,"startTime":"0","endTime":"0","summary":"科伦药业发布公告，公司子公司湖南科伦制药有限公司的化学药品“奥拉帕利片”于近日获得国家药品监督管理局的药品注册批准。奥拉帕利片为国家医保乙类品种，2022年中国销售14亿元。目前公司已有系列抗肿瘤药物获批，本次奥拉帕利片为国产第2家获批，将进一步丰富公司在肿瘤领域的产品管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-19/doc-inaczzqe1340043.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-19/doc-inaczzqe1340043.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2404279758","title":"科伦药业2023年业绩预增近50%，但ADC赛道日渐拥挤","url":"https://stock-news.laohu8.com/highlight/detail?id=2404279758","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2404279758?lang=zh_cn&edition=full","pubTime":"2024-01-17 09:24","pubTimestamp":1705454640,"startTime":"0","endTime":"0","summary":"　　作为新兴的抗癌疗法，ADC药物技术近年来发展迅速，全球各大药厂争相进入这个赛道。　　科伦药业1月16日披露2023年业绩预告，主营业务维持稳健增长的同时，ADC药物授权带来的确认收入增加和减亏是全年业绩增长的主要原因之一。　　目前科伦药业旗下科伦博泰在研ADC药物管线超过30个，且覆盖了TROP2、HER2和CLDN18.2等多个靶点。考虑到ADC创新药在全球范围内景气度持续高企，其或将成为科伦药业未来主要的增长动力来源。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-01-17/doc-inacuwnf6668057.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-01-17/doc-inacuwnf6668057.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2403636019","title":"科伦药业(002422.SZ)发预增，2023年度预盈23.5亿元至25.5亿元 增长37.82%-49.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2403636019","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2403636019?lang=zh_cn&edition=full","pubTime":"2024-01-15 20:50","pubTimestamp":1705323000,"startTime":"0","endTime":"0","summary":"转自：金融界本文源自:智通财经网智通财经APP讯，科伦药业发布2023年度业绩预告，预计全年归属于上市公司股东的净利润23.5亿元至25.5亿元，同比增长37.82%-49.55%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-01-15/doc-inacrmtu5461908.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-01-15/doc-inacrmtu5461908.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-06-03","address":"四川省成都市新都区新都卫星城工业开发区南二路","stockEarnings":[{"period":"1week","weight":0.1275},{"period":"1month","weight":0.1113},{"period":"3month","weight":0.4684},{"period":"6month","weight":0.2301},{"period":"1year","weight":0.0896},{"period":"ytd","weight":0.1687}],"companyName":"四川科伦药业股份有限公司","boardCode":"AI0027","perCapita":"44657股","boardName":"医药制造业","registeredCapital":"160159万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":"　　四川科伦药业股份有限公司主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等25种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。主要产品涵盖麻醉镇痛、中枢神经、抗感染、肠外营养等领域。三年来，已实现41项仿制药连续获批上市，16个品种通过一致性评价，2个品种创新药物开展中美临床研究，新一代肿瘤免疫药物A293获批临床，首个创新药物A167完成关键II期临床疗效评估。公司作为国内医药创新和高质量发展的代表企业，荣获“中国制药集团研发20强”、“2019年中国医药研发产品线最佳工业企业”等荣誉称号。","serverTime":1714652181858,"listedPrice":83.36,"stockholders":"29266人(较上一季度减少0.08%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦药业,002422,科伦药业股票,科伦药业股票老虎,科伦药业股票老虎国际,科伦药业行情,科伦药业股票行情,科伦药业股价,科伦药业股市,科伦药业股票价格,科伦药业股票交易,科伦药业股票购买,科伦药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}